Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN versus E E S 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN versus E E S 400.
BIAXIN vs E.E.S. 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
None Documented
None Documented
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic